4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.

      1 , 2 , 3
      Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
      Elsevier BV
      AF, Anticoagulants/Administration and Dosage, Atrial Fibrillation, CrCl, DTI, DVT, DXI, Drug Administration Schedule, Drug Monitoring, ERCP, Endoscopy, FDA, FEIBA, FVII, Factor VII, Factor VIII inhibitor bypass activity, Food and Drug Administration, GI, Gastrointestinal, MI, PCC, PCI, PE, PT, TT, Thrombosis/Drug Therapy, aPTT, activated partial thromboplastin time, atrial fibrillation, creatinine clearance, deep venous thrombosis, direct factor X inhibitor, direct thrombin inhibitor, endoscopic retrograde cholangiopancreatography, gastrointestinal, myocardial infarction, percutaneous coronary intervention, prothrombin complex concentrate, prothrombin time, pulmonary embolism, rFVIIa, recombinant FVIIa, thrombin time

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A large number of patients worldwide receive anticoagulant and antiplatelet agents, collectively known as antithrombotic agents. Several new anticoagulants and antiplatelet agents recently were approved for use. Gastroenterologists may be unfamiliar with the mechanism of action, indications for use, and pharmacokinetics of these newer drugs. In patients undergoing elective and urgent endoscopic procedures, clinicians must be familiar with these medications to optimize outcomes. When the decision is made to continue the newer antithrombotic agents for elective procedures, the clinician must understand the risk that these agents may impart on procedural-induced bleeding. Finally, it is important to understand how to manage these agents in the presence of acute gastrointestinal bleeding. In this article the use of newer antithrombotic agents is reviewed.

          Related collections

          Author and article information

          Journal
          Clin. Gastroenterol. Hepatol.
          Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
          Elsevier BV
          1542-7714
          1542-3565
          Feb 2014
          : 12
          : 2
          Affiliations
          [1 ] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: baron.todd@mayo.edu.
          [2 ] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
          [3 ] Division of Cardiovascular Diseases, Division of Hematology, Mayo Clinic, Rochester, Minnesota.
          Article
          S1542-3565(13)00731-3
          10.1016/j.cgh.2013.05.020
          23735447
          2d3fafa2-d620-4b14-b414-4fea8bbbaf3e
          History

          AF,Anticoagulants/Administration and Dosage,Atrial Fibrillation,CrCl,DTI,DVT,DXI,Drug Administration Schedule,Drug Monitoring,ERCP,Endoscopy,FDA,FEIBA,FVII,Factor VII,Factor VIII inhibitor bypass activity,Food and Drug Administration,GI,Gastrointestinal,MI,PCC,PCI,PE,PT,TT,Thrombosis/Drug Therapy,aPTT,activated partial thromboplastin time,atrial fibrillation,creatinine clearance,deep venous thrombosis,direct factor X inhibitor,direct thrombin inhibitor,endoscopic retrograde cholangiopancreatography,gastrointestinal,myocardial infarction,percutaneous coronary intervention,prothrombin complex concentrate,prothrombin time,pulmonary embolism,rFVIIa,recombinant FVIIa,thrombin time

          Comments

          Comment on this article